Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Senesco Technologies Inc. (ELOX : NSDQ)
 
 • Company Description   
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.00 Daily Weekly Monthly
20 Day Moving Average: 45,991 shares
Shares Outstanding: 4.04 (millions)
Market Capitalization: $60.55 (millions)
Beta: -1,862.26
52 Week High: $23.40
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.77% -11.37%
12 Week 2.04% -0.13%
Year To Date 1,363,399.88% 1,209,165.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10 Court Street P.O. Box 274
-
ARLINGTON,MA 02476
USA		 ph: 781-577-5300
fax: 908-864-4440		 ir@bgstaffing.com http://www.eloxxpharma.com
 
 • General Corporate Information   
Officers
Sumit Aggarwal - President; Chief Executive Officer and Director
Alan Walts - Chairman and Director
Daniel E. Geffken - Chief Financial Officer
Steven D. Rubin. - Director
Steven D. Rubin - Director

Peer Information
Senesco Technologies Inc. (CORR.)
Senesco Technologies Inc. (RSPI)
Senesco Technologies Inc. (CGXP)
Senesco Technologies Inc. (BGEN)
Senesco Technologies Inc. (GTBP)
Senesco Technologies Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29014R301
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/10/26
Share - Related Items
Shares Outstanding: 4.04
Most Recent Split Date: 6.00 (0.09:1)
Beta: -1,862.26
Market Capitalization: $60.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/10/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.30
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 25.01%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/26 - -
03/31/26 - -
12/31/25 - -
ROA
06/30/26 - -
03/31/26 - -
12/31/25 - -
Current Ratio
06/30/26 - 3.74
03/31/26 - 0.53
12/31/25 - 0.31
Quick Ratio
06/30/26 - 3.74
03/31/26 - 0.53
12/31/25 - 0.31
Operating Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -
Net Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -
Pre-Tax Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -
Book Value
06/30/26 - 11.50
03/31/26 - -16.45
12/31/25 - -
Inventory Turnover
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Equity
06/30/26 - 0.00
03/31/26 - -
12/31/25 - -
Debt-to-Capital
06/30/26 - 0.00
03/31/26 - -
12/31/25 - -
 

Powered by Zacks Investment Research ©